DDInter921 DDInter899
Indometacin, or indomethacin, is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic properties. NSAIDs consist of agents that are structurally unrelated; the NSAID chemical classification of indometacin is an indole-acetic acid derivative with the chemical name 1- (p-chlorobenzoyl)25-methoxy-2-methylindole-3-acetic acid. The pharmacological effect of indometacin is not fully understood, however, it is thought to be mediated through potent and nonselective inhibition of the enzyme cyclooxygenase (COX), which is the main enzyme responsible for catalyzes the rate-limiting step in prostaglandin and thromboxane biosynthesis via the arachidonic acid (AA) pathway. Indometacin was first discovered in 1963 and it was first approved for use in the U.S. by
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Indomethacin {u} (Compound) resembles {v} (Compound) Agomelatine
Indomethacin {u} (Compound) resembles {v} (Compound) Fenofibrate
Indomethacin {u} (Compound) treats {v} (Disease) gout
Indomethacin {u} (Compound) binds {v} (Gene) PTGR2
Indomethacin {u} (Compound) upregulates {v} (Gene) TIAM1
Indomethacin {u} (Compound) palliates {v} (Disease) osteoarthritis
Indomethacin {u} (Compound) is included by {v} (Pharmacologic Class) Nonsteroidal Anti-inflammatory Compounds
Indomethacin {u} (Compound) downregulates {v} (Gene) COG2
Indomethacin {u} (Compound) causes {v} (Side Effect) Sweating
Indomethacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Indomethacin (Compound) resembles Agomelatine (Compound)
Indomethacin (Compound) resembles Fenofibrate (Compound)
Indomethacin (Compound) treats gout (Disease)
Indomethacin (Compound) binds PTGR2 (Gene)
Indomethacin (Compound) upregulates TIAM1 (Gene)
Indomethacin (Compound) palliates osteoarthritis (Disease)
Indomethacin (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class)
Indomethacin (Compound) downregulates COG2 (Gene)
Indomethacin (Compound) causes Sweating (Side Effect)
Indomethacin may cause a minor interaction that can limit clinical effects when taken with Cimetidine